Skip to main content
Utility menu
Donate
Join
Member Login
Search
Learn About Us
Learn About Us
Strategic Plan
Board of Directors
Committees
Awards
Staff
Contact
Support The Mission
Support The Mission
Partners for Thoracic Cancer Care
Legacy Society
IASLC Global Member Survey on Inclusivity
Celebrate IASLC's 50th Anniversary
Celebrate IASLC's 50th Anniversary
History
WCLC 2024 Highlights
Access Online Learning
Conferences & Webinars
Conferences & Webinars
Upcoming Conferences & Webinars
Past Conferences & Webinars
WCLC 2024
Research & Education
Research & Education
Scientific Projects
Scientific Projects
IASLC Staging Project: Lung Cancer, Thymic Tumors, and Mesothelioma
IASLC Global Survey on Biomarker Testing in Lung Cancer 2024 Update
IASLC Neoadjuvant Therapy in Lung Cancers Initiatives
IASLC Atlas of Molecular Testing for Targeted Therapy in Lung Cancer
ELIC
Past IASLC Scientific Projects
Lung Cancer 360
Journals
Journals
Journal of Thoracic Oncology
JTO Clinical and Research Reports (JTO CRR)
IASLC Reviewer Workshop
Early-Career Opportunities
IASLC Academy
IASLC Academy
Amazing Case Race 2024
Publications, Resources & Guidelines
News
News
ILCN
WCLC 2024 News
Press Releases
Lung Cancer Considered Podcast
Membership
Membership
Become a Member
Renew Your Membership
IASLC Partnerships
Patient Advocacy
Patient Advocacy
STARS
Lung Cancer Awareness Month 2023 Highlights
Foundation
Foundation
Donor Recognition
Research Grant Program
Grant Recipient Spotlights
Research Grant Recipients
Search
Fulltext search
Fulltext search
Search
Displaying 1 - 12 items out of 50 results
ILCN article
Lung Cancer Diagnosis and Staging During COVID-19
ILCN article
IASLC Staging Project Finalizing Recommendations for 9th Edition of TNM Classification System
ILCN article
Staging Experts Offer Insights on Challenges of Nodal Classification
ILCN article
Real-World Data Shows Less Benefit for Mesothelioma from Checkpoint Inhibitors Vs. Clinical Trials
ILCN article
Real-World Data Show That Survival Just as Good With Carboplatin Therapy as With Cisplatin Therapy in Malignant Pleural Mesothelioma
ILCN article
Pembrolizumab Considered for Second Tissue-Agnostic Cancer Indication
ILCN article
New FDA Commissioner Confirmed
ILCN article
Dr. Richard Pazdur Discusses Project Facilitate and the Expanded-Access Program
ILCN article
NCI Director Dr. Norman E. Sharpless Discusses 2019 Budget Plans During Social Media Event
ILCN article
FDA Approval Processes in the Era of Targeted Therapies: A Conversation with Dr. Richard Pazdur
ILCN article
NCI Corner: Racial Differences in the Transcriptomes of Lung Tumors
ILCN article
NCI Selects Five Teams of Researchers to Expand Discovery of Predictive Biomarkers for Immunotherapy
Pagination
1
2
3
4
5
›
Next page
Last
Last page